ImageneBio Inc
IMA
NASDAQ·Healthcare·Biotechnology·Mkt cap $54.7M
$4.85
▼ -0.72%
P/E
—
Mkt Cap
$54.7M
52-Wk Range
$3.94–$9.47
52-Week Range
$3.94 - $9.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 47.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary non-depleting anti-OX40 monoclonal antibody technology
- Differentiated mechanism of action in I&I disease treatment
- Advanced clinical development stage with Phase 2b trials
- Focused pipeline strategy targeting high-value indications
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Phase 2b clinical trial progression for IMG-007 in atopic dermatitis
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-13.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 5, 2026
Reported EPS of -$0.63 vs -$0.98 consensus (+35.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+35.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
0%
Sell
50%
Median Price Target
—
Latest: HC Wainwright · Aug 21, 2026
vs Industry
How IMA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related